What the General Practitioner Needs to Know: When to Consult the Cardiologist and/or the Oncologist

  • Chiara Lestuzzi
  • Olivia Maria Thomas
  • Maria Agnese Caggegi
  • Francesco Ferraù
Chapter

Abstract

Most patients undergoing antineoplastic treatments with anthracyclines and trastuzumab—well known to be potentially cardiotoxic—have a cardiology follow-up planned by the oncologists. Any obvious side effects occurring during treatments administered in hospital or in the day hospital unit will be referred to the local cardiologist.

References

  1. 1.
    Watson M, Lucas C, Hoy A, Wells J. Oxford handbook of palliative care. 2nd ed. Oxford: Oxford University Press; 2009 (Chapter 6L-Palliative Haematological Aspects).Google Scholar
  2. 2.
    Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Carrier M, Le Gal G, Cho R, et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost. 2009;7:760–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: prophylaxis in medical patients with enoxaparin study group. N Engl J Med. 1999;341:793–800.CrossRefPubMedGoogle Scholar
  5. 5.
    Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10:943–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011;29:986–93.CrossRefPubMedGoogle Scholar
  7. 7.
    Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomised prospective trial. Ann Intern Med. 1990;112:423–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Monreal M, Alastrue A, Rull M, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices: prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost. 1996;75:251–3.PubMedGoogle Scholar
  9. 9.
    Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med J. 2002;32:84–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Couban S, Goodyear M, Burnell M, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol. 2005;23:4063–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Karthaus M, Kretzschmar A, Kroning H, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol. 2006;17:289–96.CrossRefPubMedGoogle Scholar
  12. 12.
    Verso M, Agnelli G, Bertoglio S, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol. 2005;23:4057–62.CrossRefPubMedGoogle Scholar
  13. 13.
    Geerts W. Central venous catheter-related thrombosis. Hematology Am Soc Hematol Educ Program. 2014;2014:306–11.PubMedGoogle Scholar
  14. 14.
    Sriskandarajah P, Webb K, Chisholm D, et al. Retrospective cohort analysis comparing the incidence of deep vein thromboses between peripherally-inserted and long-term skin tunneled venous catheters in hemato-oncology patients. Thromb J. 2015;13:21.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Chaukiyal P, Nautiyal A, Radhakrishnan S, et al. Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis. Thromb Haemost. 2008;99:38–43.PubMedGoogle Scholar
  16. 16.
    Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA. 2003;290:465–75.CrossRefPubMedGoogle Scholar
  17. 17.
    Travis LB, Ng AK, Allan JM, et al. Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst. 2012;104:357–70.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Thiagarajan A, Iyer NG. Radiation-induced sarcomas of the head and neck. World J Clin Oncol. 2014;5:973–81. Review.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Choi DK, Helenowski I, Hijiya N. Secondary malignancies in pediatric cancer survivors: perspectives and review of the literature. Int J Cancer. 2014;135:1764–73. Review.CrossRefPubMedGoogle Scholar
  20. 20.
    Dudgeon DJ, Lertzman M. Dyspnea in advanced cancer patient. J Pain Symptom Manage. 1998;16:212–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Bruera E. The frequency and correlates of dyspnoea in patients with advanced cancer. J Pain Symptom Manage. 2000;19:357–62.CrossRefPubMedGoogle Scholar
  22. 22.
    Watson M, et al. Respiratory symptoms, Oxford handbook of palliative care. 2nd ed. Oxford: Oxford University Press; 2009. p. 363–75.Google Scholar
  23. 23.
    Brown DJF. Palliation of breathlessness. Clin Med. 2006;6:133–6.CrossRefGoogle Scholar
  24. 24.
    Goody R. Using oxygen therapy in the palliative care setting. Eur J Palliat Care. 2007;14:120–3.Google Scholar
  25. 25.
    Vermeulen LC, et al. A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions. Arch Intern Med. 1995;155(16):1817.Google Scholar
  26. 26.
    Adrogué HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N Engl J Med. 2007;356:1966–78. Review.CrossRefPubMedGoogle Scholar
  27. 27.
    Penton D, Czogalla J, Loffing J. Dietary potassium and the renal control of salt balance and blood pressure. Pflugers Arch. 2015;467:513–30.CrossRefPubMedGoogle Scholar
  28. 28.
    American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: ACCP E-BCPG (8 th Edition). Chest. 2008;133 Suppl 6:454S–545.Google Scholar
  29. 29.
    Trentin L. Valutazione e Trattamento dei sintomi nel malato oncologico. 2015 Edition. AIOM (Associazione Italiana di Oncologia Medica) with contribution of ESMO (European Society for Medical Oncology).Google Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Chiara Lestuzzi
    • 1
  • Olivia Maria Thomas
    • 2
  • Maria Agnese Caggegi
    • 2
  • Francesco Ferraù
    • 3
  1. 1.Cardiology UnitIRCCS CRO-National Cancer InstituteAviano (PN)Italy
  2. 2.Il Gabbiano Hospice and Community Palliative Care ServiceFriuli OccidentaleItaly
  3. 3.Medical Oncology UnitOspedale San VincenzoTaorminaItaly

Personalised recommendations